Interleukin-13 and cardiovascular diseases: literature review
Authors:
- Amina Magomedovna AlievaAAAmina Magomedovna Alieva
- Elena Vladimirovna ReznikERElena Vladimirovna Reznik
- Natalia Vadimovna TeplovaNTNatalia Vadimovna Teplova
- Leyla Ramazanovna SarakaevaLSLeyla Ramazanovna Sarakaeva
- Elena Valerievna SurskayaESElena Valerievna Surskaya
- Dzhannet Anuarovna ElmurzaevaDEDzhannet Anuarovna Elmurzaeva
- Madina Yakubovna ShavaevaMSMadina Yakubovna Shavaeva
- Alik Magomedovich RakhaevARAlik Magomedovich Rakhaev
- Irina Aleksandrovna KotikovaIKIrina Aleksandrovna Kotikova
- Igor Gennadievich NikitinINIgor Gennadievich Nikitin
- 10 October 2022
- journal article
- review article
- Published by ECO-Vector LLC in Russian Medicine
- Vol. 28 (4) , 291-304
Abstract
Cardiovascular diseases remain the leading cause of death worldwide despite significant advances in medicine and increased life expectancy. It is very important to search for and study new cardiovascular biological markers that can help the early diagnosis of cardiovascular diseases, serve as a laboratory tool for assessing the effectiveness of treatment, be a predictive marker of possible adverse clinical outcomes, and be a significant criterion for risk stratification. This review aims to consider interleukin-13 (IL-13) as a diagnostic and prognostic biomarker in cardiovascular pathology. IL-13 is involved in the development of many cardiovascular diseases, according to variousin vitroandin vivostudies, but its role remains unclear until the end. IL-13 has a positive effect, promoting the development of the heart at an early stage and facilitating the recovery of the heart after a myocardial infarction. Due to the induction of fibrosis and adverse cardiac remodeling, long-term IL-13 synthesis appears to be a risk factor for adverse outcomes in chronic cardiovascular diseases, such as heart failure. Understanding the effect of IL-13 on cardiac metabolism will shed light on possible new pathogenetic mechanisms for the development of heart disease. As a rule, an increase in the level of IL-13 in the blood serum goes in parallel with its expression in the tissues of the heart. However, the dissociation of systemic inflammatory reactions and local expression is not excluded. The introduction of IL-13 can restore the regenerative capacity of cardiomyocytes and reduce cardiac dysfunction. IL-13 deficiency limits the proliferation of cardiomyocytes, induces compensatory hypertrophy of cardiomyocytesin vitroand deletion of IL-13, leads to cardiac dysplasia, and impairs recovery processesin vivo. Although IL-13 is associated with cardiac fibrosis, cardiomyocyte proliferation, myocardial hypertrophy, immune cell recruitment and differentiation, and chemokine secretion in the heart, it is precise signaling pathways and underlying mechanisms of action remain poorly understood.Keywords
This publication has 67 references indexed in Scilit:
- Type 2 innate lymphoid cells control eosinophil homeostasisNature, 2013
- Combined Use of the Novel Biomarkers High-Sensitivity Troponin T and ST2 for Heart Failure Risk Stratification vs Conventional AssessmentMayo Clinic Proceedings, 2013
- Changes in the Monocytic Subsets CD14dimCD16+and CD14++CD16−in Chronic Systolic Heart Failure PatientsMediators of Inflammation, 2012
- Interleukin‐13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotypeEMBO Molecular Medicine, 2012
- Multiple Biomarkers for Risk Prediction in Chronic Heart FailureCirculation: Heart Failure, 2012
- Association of systemic inflammation markers with the presence and extent of coronary artery calcificationCytokine, 2012
- Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heartJournal of Molecular and Cellular Cardiology, 2011
- Increased interleukin-13 levels in patients with chronic heart failureInternational Journal of Cardiology, 2009
- Interleukin-13 Protects Against Experimental Autoimmune Myocarditis by Regulating Macrophage DifferentiationThe American Journal of Pathology, 2008
- Serum Markers of Angiogenesis and Myocardial Ultrasonic Tissue Characterization in Patients with Dilated CardiomyopathyEuropean Journal of Heart Failure, 2005